Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Invir.IO

First Patient Dosed in Phase 1 Trial Evaluating Transgene’s and BioInvent’s BT-001 in Patients with Rectal Cancer

BT-001 rectacl cancer

Published 5 November 2026
Categorized as 2026, 2026, BT-001, Invir.IO, Press release

Colorectal Cancer Hepatic Metastasis Modeling by Advanced 3D Bioprinting Allows Demonstration of Oncolytic Viral Chemotherapeutic Delivery

P. Erbs, et al. Cancers 2025 Abstract available on the MDPI website – Download the article

Published 19 November 2025
Categorized as -others, 2025, Invir.IO, Publication, TG6002

Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025

ESMO 2025

Published 27 July 2025
Categorized as 2025, BT-001, Invir.IO, Press release

TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery

J. Foloppe, et al. IOVC 2024  Abstract available on the IOVC website – Download the abstract and the poster

Published 27 October 2024
Categorized as -others, 2024, Invir.IO, Publication

Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and influence their immunogenicity

U. Hirigoyen, et al. Oncology 2024 Article available on the Molecular Therapy Oncology website – Download the Article

Published 24 September 2024
Categorized as -others, 2024, Invir.IO, Publication

TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvionment

L.Fend, et al. ESMO 2024  Abstract available on the CICON website – Download the abstract and the poster

Published 10 September 2024
Categorized as 2024, Invir.IO, Publication, TG6050-en

Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Transgene to present data on its two therapeutic cancer vaccines at the 2023 ASCO annual meeting

Published 26 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Invir.IO, Myvac, Press release, TG4001, TG4050

Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors

Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001

Published 25 May 2023
Categorized as 2023, BT-001, categorie-orpheline, dates, dates, Invir.IO, Press release

Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer

First patient dosed in Phase I trial evaluating TG6050 15

Published 10 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Invir.IO, Press release, TG6050-en

Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy

H. Le et al.AACR 2023Download the poster herePoster Presentation

Published 19 April 2023
Categorized as -others, 2023, Invir.IO, Publication

Posts pagination

Page 1 … Page 6 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu